Updated:
Receptor Partners
Receptor Partners invests in the clinical pipeline of psychedelic medicine, with a portfolio of eight companies including Beckley Psytech, Psilera, and...
Receptor Partners
Receptor Partners is a private equity firm based in New York, US. It focuses on a Venture Capital investment approach.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Sector focus
Frequently asked questions
What is Receptor Partners' investment thesis?
The firm targets the emerging regulatory pathway for psychedelic-derived therapeutics. It invests in companies developing compounds for mental health conditions, including depression, anxiety, and substance-use disorders. The portfolio spans discovery-stage platform companies and clinical-stage drug developers.
Which companies are in Receptor Partners' disclosed portfolio?
The firm's website lists eight positions: Beckley Psytech, Psilera, MindState Design, BrightMinds, Tactogen, Delix, Freedom Biosciences, and Cybin. These companies range from private preclinical-stage ventures to publicly traded clinical-stage biotechs.
How does Receptor Partners source its investments?
The firm does not publicly describe its sourcing model. Given the small, specialized pool of psychedelic drug developers, its deal flow likely depends on direct relationships with founders and scientific networks rather than broad origination.
Does Receptor Partners lead rounds or participate as a co-investor?
The firm has not disclosed its typical check size, ownership targets, or whether it leads financings. Its presence across eight portfolio companies suggests a capital-light, minority-position strategy, but no details are public.
Who manages investment decisions at Receptor Partners?
Receptor Partners has not named any principals, investment committee members, or deal leads on its website or in any other public source that Altss could identify.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: